An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer
about
Loss of PTEN expression in breast cancer: association with clinicopathological characteristics and prognosis.miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN.The Therapeutic Challenge of Targeting HER2 in Endometrial CancerPrognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer.Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer.Proteins Involved in HER2 Signalling Pathway, Their Relations and Influence on Metastasis-Free Survival in HER2-Positive Breast Cancer Patients Treated with Trastuzumab in Adjuvant SettingThe impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.Mutation distributions and clinical correlations of PIK3CA gene mutations in breast cancer.Progression inference for somatic mutations in cancer.PIK3CA mutations and their response to neoadjuvant treatment in early breast cancer: A systematic review and meta-analysis.Novel mutations of PIK3CA gene in head and neck squamous cell carcinoma.Evaluation of PIK3CA mutations as a biomarker in Chinese breast carcinomas from Western China.Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.Neoadjuvant chemotherapy in breast cancer: a dose-dense schedule in real life and putative role of PIK3CA mutations.
P2860
Q33762003-65AD9BC3-2191-4F6C-8CCD-01FDBD669F39Q35741033-54025F38-7A35-4010-AF38-24C8019E2B1CQ36064912-0CC93285-C862-4B02-98CF-B82132842579Q36467458-3123DB0B-ADA3-418F-B71D-A501FE072507Q37328400-1A72AB21-6866-4A1A-BC9C-C431DC1867D9Q37604329-BE0F286E-B31D-471A-8F2E-338351F3C03DQ37737145-2AADD6A3-5048-47F3-87AF-3EC619306B83Q38752466-C392F35B-224A-4D0E-8A1C-17606098C8BDQ38793244-DC1F6F8D-692C-422E-97F8-322591EFB554Q52633197-93193C0F-A3AA-40C4-AA3D-20A95C61D17DQ53206186-4D98773A-7BFE-4F63-B15C-59D54AB73232Q55003988-19569226-3DFD-4A09-88B3-B54A335789F0Q55070669-D71BBDEF-2821-47B8-9C03-48A6FFF2B205Q55428234-AB4BBE67-3633-4D94-B67C-617CB3E2E0F0
P2860
An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
An integrative analysis of PIK ...... in HER2-positive breast cancer
@ast
An integrative analysis of PIK ...... in HER2-positive breast cancer
@en
An integrative analysis of PIK ...... in HER2-positive breast cancer
@nl
type
label
An integrative analysis of PIK ...... in HER2-positive breast cancer
@ast
An integrative analysis of PIK ...... in HER2-positive breast cancer
@en
An integrative analysis of PIK ...... in HER2-positive breast cancer
@nl
prefLabel
An integrative analysis of PIK ...... in HER2-positive breast cancer
@ast
An integrative analysis of PIK ...... in HER2-positive breast cancer
@en
An integrative analysis of PIK ...... in HER2-positive breast cancer
@nl
P2093
P2860
P1433
P1476
An integrative analysis of PIK ...... in HER2-positive breast cancer
@en
P2093
Aiko Sueta
Hirotaka Iwase
Mutsuko Yamamoto-Ibusuki
Satoko Yamamoto
Yutaka Yamamoto
P2860
P304
P356
10.1371/JOURNAL.PONE.0116054
P407
P577
2014-12-26T00:00:00Z